TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Resynchronization/Defibrillation for Ambulatory Heart Failure Trial
Brief Summary: Congestive heart failure (CHF) is a common health problem that leads to frequent hospitalizations and an increased death rate. In spite of advances in drug therapy, it remains a significant public health problem. Recently, a new therapy has been developed for advanced heart failure patients with a ventricular conduction abnormality. This new therapy, called cardiac resynchronization (CRT), is a device which stimulates the atrium, the right ventricle, and the left ventricle providing synchronization of the contraction of the heart chambers. It is the addition of this therapy to an implantable cardioverter defibrillator (ICD) that will be evaluated in this study. This study will compare whether the implantation of this new therapy device, in combination with an implantable cardioverter defibrillator, will reduce total mortality and hospitalizations for CHF.


Options:
A: Combination of all-cause mortality and first hospitalization (time to first event), where all-cause mortality is defined as death from all causes.
B: Mortality, Heart Failure-related Urgent Care Visits, or Significant Increase in Left Ventricular End Systolic Volume Index (LVESVI) (Participants were followed for the duration of the study, an average of 39.8 months post-randomization.)
C: Incidences of Appropriate Therapies (ATP and Shocks) and ICD-Related Complications (3-year)
D: Primary outcome is a composite of all cause total mortality and hospitalization for CHF (Study end)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Catheter-directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis, an Open Randomized, Controlled, Clinical Trial
Brief Summary: Deep vein thrombosis (DVT) is a severe disease, and conventional treatment with low molecular weight heparin (LMWH) and warfarin is associated with some degree of long-term sequelae, i.e. post-thrombotic syndrome (PTS). Catheter-directed thrombolytic (CDT) therapy has been introduced worldwide the last two decades. Reports have suggested a beneficial effect of this costly treatment, but there are no randomized clinical trials documenting its short- and long-term efficacy and safety. This multi-center study will randomize patients with acute iliofemoral vein thrombosis to either conventional treatment or CDT in addition to conventional treatment. Main outcome parameters are patency rates at 6 months and prevalence of PTS at 24 months. The main short-term hypothesis is that CDT of first-time acute DVT will increase patency of the affected segments after 6 months from \<50% to \>80%. The main long-term hypothesis is that CDT will improve long-term functional outcome, i.e. risk of PTS after 2 years from \>25% to \<10%.


Options:
A: Venous thrombosis and/or pulmonary embolism (PE) (Postoperative 4 weeks)
B: Patency after 6 months (6 months); Post-thrombotic syndrome after 2 years (yrs) (2 years)
C: low molecular weight heparin (enoxaparin) and ventilatory support time (30 days); thrombotic complications and Rivaroxaban (30 days); low molecular weight heparin (enoxaparin) and length of hospital stay (30 days); low molecular weight heparin (enoxaparin) and mortality rate (30 days)
D: Incidence of Post-thrombotic Syndrome (PTS) (During 2-year follow up)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Catheter-directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis, an Open Randomized, Controlled, Clinical Trial
Brief Summary: Deep vein thrombosis (DVT) is a severe disease, and conventional treatment with low molecular weight heparin (LMWH) and warfarin is associated with some degree of long-term sequelae, i.e. post-thrombotic syndrome (PTS). Catheter-directed thrombolytic (CDT) therapy has been introduced worldwide the last two decades. Reports have suggested a beneficial effect of this costly treatment, but there are no randomized clinical trials documenting its short- and long-term efficacy and safety. This multi-center study will randomize patients with acute iliofemoral vein thrombosis to either conventional treatment or CDT in addition to conventional treatment. Main outcome parameters are patency rates at 6 months and prevalence of PTS at 24 months. The main short-term hypothesis is that CDT of first-time acute DVT will increase patency of the affected segments after 6 months from \<50% to \>80%. The main long-term hypothesis is that CDT will improve long-term functional outcome, i.e. risk of PTS after 2 years from \>25% to \<10%.


Options:
A: To estimate the prevalence of asymptomatic deep venous thrombosis and pulmonary emboli in obese patients undergoing bariatric surgery. (2 years)
B: Hospital Admission (21 days); Hospital Admission (50 days); Hospital Admission (90 days); Death (21 days); Death (50 days); Death (90 days)
C: Patency after 6 months (6 months); Post-thrombotic syndrome after 2 years (yrs) (2 years)
D: Hospitalization for Cardiovascular/Pulmonary Events (45 days)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Catheter-directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis, an Open Randomized, Controlled, Clinical Trial
Brief Summary: Deep vein thrombosis (DVT) is a severe disease, and conventional treatment with low molecular weight heparin (LMWH) and warfarin is associated with some degree of long-term sequelae, i.e. post-thrombotic syndrome (PTS). Catheter-directed thrombolytic (CDT) therapy has been introduced worldwide the last two decades. Reports have suggested a beneficial effect of this costly treatment, but there are no randomized clinical trials documenting its short- and long-term efficacy and safety. This multi-center study will randomize patients with acute iliofemoral vein thrombosis to either conventional treatment or CDT in addition to conventional treatment. Main outcome parameters are patency rates at 6 months and prevalence of PTS at 24 months. The main short-term hypothesis is that CDT of first-time acute DVT will increase patency of the affected segments after 6 months from \<50% to \>80%. The main long-term hypothesis is that CDT will improve long-term functional outcome, i.e. risk of PTS after 2 years from \>25% to \<10%.


Options:
A: Patency after 6 months (6 months); Post-thrombotic syndrome after 2 years (yrs) (2 years)
B: N/A
C: Incidence of Post-thrombotic Syndrome (PTS) (During 2-year follow up)
D: Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale) (Between 6 and 24 months after randomization)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Catheter-directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis, an Open Randomized, Controlled, Clinical Trial
Brief Summary: Deep vein thrombosis (DVT) is a severe disease, and conventional treatment with low molecular weight heparin (LMWH) and warfarin is associated with some degree of long-term sequelae, i.e. post-thrombotic syndrome (PTS). Catheter-directed thrombolytic (CDT) therapy has been introduced worldwide the last two decades. Reports have suggested a beneficial effect of this costly treatment, but there are no randomized clinical trials documenting its short- and long-term efficacy and safety. This multi-center study will randomize patients with acute iliofemoral vein thrombosis to either conventional treatment or CDT in addition to conventional treatment. Main outcome parameters are patency rates at 6 months and prevalence of PTS at 24 months. The main short-term hypothesis is that CDT of first-time acute DVT will increase patency of the affected segments after 6 months from \<50% to \>80%. The main long-term hypothesis is that CDT will improve long-term functional outcome, i.e. risk of PTS after 2 years from \>25% to \<10%.


Options:
A: Post thrombotic syndrome (percentage of patients with PTS) one year following the acute thrombotic event. (one year)
B: Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale) (Between 6 and 24 months after randomization)
C: Improvement of Total EKOS Thrombus Score, a specifically developed venographic scoring system (After 15 hours of CDT)
D: Patency after 6 months (6 months); Post-thrombotic syndrome after 2 years (yrs) (2 years)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Catheter-directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis, an Open Randomized, Controlled, Clinical Trial
Brief Summary: Deep vein thrombosis (DVT) is a severe disease, and conventional treatment with low molecular weight heparin (LMWH) and warfarin is associated with some degree of long-term sequelae, i.e. post-thrombotic syndrome (PTS). Catheter-directed thrombolytic (CDT) therapy has been introduced worldwide the last two decades. Reports have suggested a beneficial effect of this costly treatment, but there are no randomized clinical trials documenting its short- and long-term efficacy and safety. This multi-center study will randomize patients with acute iliofemoral vein thrombosis to either conventional treatment or CDT in addition to conventional treatment. Main outcome parameters are patency rates at 6 months and prevalence of PTS at 24 months. The main short-term hypothesis is that CDT of first-time acute DVT will increase patency of the affected segments after 6 months from \<50% to \>80%. The main long-term hypothesis is that CDT will improve long-term functional outcome, i.e. risk of PTS after 2 years from \>25% to \<10%.


Options:
A: All-cause mortality at day 28 (Day 28 from randomization)
B: Patency after 6 months (6 months); Post-thrombotic syndrome after 2 years (yrs) (2 years)
C: Number of Participants With Grade 3 and Grade 4 Adverse Events (AEs) Through Day 35 (Up to Day 35); Number of Participants With AEs Resulting in Study Intervention Discontinuation Through Day 35 (Up to Day 35); Number of Participants With Serious Adverse Events Through Day 35 (Up to Day 35); Number of Participants Who Progressed to Moderate or Severe Disease or Higher Based on the Gates MRI Ordinal Scale Through Day 28 (Up to Day 28)
D: a composite of acute VTE, arterial thrombosis, treatment with ECMO, or all-cause mortality (30 days from enrollment)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Shared Decision-Making for Colorectal Cancer Screening
Brief Summary: The overall objective of this study is to conduct a three-arm randomized controlled trial to evaluate the impact of an interactive, web-based decision aid on shared decision-making and patient adherence to colorectal cancer (CRC) screening recommendations.


Options:
A: Quality of Decision Making (Immediately following each patient's index visit and before they leave the clinic on that day, typically within 10 minutes of completing the clinical encounter.); Knowledge Transfer (Immediately following each patient's index visit and before they leave the clinic on that day, typically within 10 minutes of completing the clinical encounter.)
B: Patient Adherence (Test Completion) (12 months post-intervention)
C: Mean Number of Skin Examinations Without Partner Over 4 Months (4 months); Mean Number of Skin Examinations With Partner Over 4 Months (4 months); Mean Number of Times Reviewed Skin Self Examination Guidelines Over 4 Months (4 months)
D: The between groups difference in the proportion of patients which achieve the treatment goals for HbA1c, blood pressure, and total cholesterol (after 12 months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Shared Decision-Making for Colorectal Cancer Screening
Brief Summary: The overall objective of this study is to conduct a three-arm randomized controlled trial to evaluate the impact of an interactive, web-based decision aid on shared decision-making and patient adherence to colorectal cancer (CRC) screening recommendations.


Options:
A: Shared Decision Making Questionnaire (CollaboRATE) (Level of Shared Decision Making at end of treatment (this will be at approximately week 8))
B: Decision to Receive an ICD (1 week post intervention)
C: Patient Adherence (Test Completion) (12 months post-intervention)
D: Change from baseline in asthma knowledge at 2 months, measured by QCALF score (Visit 1 (baseline) and visit 2 (2-month follow-up)); Change from baseline in decisional conflict at 2 months, measured by DCS score (Visit 1 (baseline) and visit 2 (2-month follow-up))

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Shared Online Health Records for Patient Safety and Care
Brief Summary: The study uses a randomized, prospective cohort design to assess the impact of shared online health records on 1) patient safety, 2) health goal adherence and outcomes, 3) documentation of family history, and 4) barriers to the adoption of patient-physician communication technology.

Hypothesis: the respective interventions will result in 1) improved patient safety 2) greater adherence to health care maintenance and chronic disease guidelines 3) more accurate documentation of family history 4) the identification of technology adoption enablers and barriers.


Options:
A: 1. ADEs; 2. duration of ameliorable medication side effects; 3. health goal adherence rates; 4. diabetes outcomes; 5. familial risk factor documentation rates; 6. user satisfaction surveys; 7. user metrics
B: Blood Pressure and Hemaglobin A1c
C: N/A
D: Hemoglobin A1c (Baseline, 6 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Shared Online Health Records for Patient Safety and Care
Brief Summary: The study uses a randomized, prospective cohort design to assess the impact of shared online health records on 1) patient safety, 2) health goal adherence and outcomes, 3) documentation of family history, and 4) barriers to the adoption of patient-physician communication technology.

Hypothesis: the respective interventions will result in 1) improved patient safety 2) greater adherence to health care maintenance and chronic disease guidelines 3) more accurate documentation of family history 4) the identification of technology adoption enablers and barriers.


Options:
A: 7-day point prevalence of smoking six months following completion of the intervention protocol (nine months post randomization). (2 years)
B: 1. ADEs; 2. duration of ameliorable medication side effects; 3. health goal adherence rates; 4. diabetes outcomes; 5. familial risk factor documentation rates; 6. user satisfaction surveys; 7. user metrics
C: Receipt of colorectal cancer screening exam (fecal occult blood test, flexible sigmoidoscopy, or colonoscopy) within 4 months following delivery of an electronic message within the personal health record
D: Body weight change (baseline and after 4weeks of lifestyle intervention)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Shared Online Health Records for Patient Safety and Care
Brief Summary: The study uses a randomized, prospective cohort design to assess the impact of shared online health records on 1) patient safety, 2) health goal adherence and outcomes, 3) documentation of family history, and 4) barriers to the adoption of patient-physician communication technology.

Hypothesis: the respective interventions will result in 1) improved patient safety 2) greater adherence to health care maintenance and chronic disease guidelines 3) more accurate documentation of family history 4) the identification of technology adoption enablers and barriers.


Options:
A: Women who participate by returning a HPV self-sampling kit or having a practitioner-collected sample in the intervention groups compared to the proportion of women who have a practitioner-collected sample in the control group at 90 days after mail out. (90 days)
B: 1. ADEs; 2. duration of ameliorable medication side effects; 3. health goal adherence rates; 4. diabetes outcomes; 5. familial risk factor documentation rates; 6. user satisfaction surveys; 7. user metrics
C: Adherence to cervical cancer screening (step1) (Up to 20 months)
D: performing a HPV test within 3 months since the recall letter (up to december 2012 (up to 3 months))

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Supportive Test for Acid-Related Symptoms (STARS I) With Esomeprazole and a Following 7-week, Double-blind, Randomized, Placebo Controlled Treatment Period in Subjects With Upper Gastrointestinal Symptoms and With Normal Findings at Esophagogastroduodenoscopy.
Brief Summary: The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment period of 7 weeks.


Options:
A: adenoma detection rate (number of polyps/number of patients examined) (6 months)
B: Detection Rates for Adenomas and for Total Polyps (Acute - subjects were followed for the duration of the procedures, an average of 40 minutes.)
C: The primary outcome is whether the patient is a responder or not after 8 weeks treatment.; The primary efficacy outcome is based on symptom score recorded daily during the study in a patient diary.; The patient will judge their symptoms of pain or burning centered in the upper abdomen on a four-graded scale (none, mild, moderate or severe).
D: polyp detection rate (1 year)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Supportive Test for Acid-Related Symptoms (STARS I) With Esomeprazole and a Following 7-week, Double-blind, Randomized, Placebo Controlled Treatment Period in Subjects With Upper Gastrointestinal Symptoms and With Normal Findings at Esophagogastroduodenoscopy.
Brief Summary: The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment period of 7 weeks.


Options:
A: The primary outcome is whether the patient is a responder or not after 8 weeks treatment.; The primary efficacy outcome is based on symptom score recorded daily during the study in a patient diary.; The patient will judge their symptoms of pain or burning centered in the upper abdomen on a four-graded scale (none, mild, moderate or severe).
B: adenoma detection rate (number of polyps/number of patients examined) (6 months)
C: Number of patients with at least one adenoma; after white light endoscopy compared with the number of patients; with at least one adenoma after white light NBI in the right colon.
D: The prevalence of adenomas in the three arms of the study. (2 years)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomised, Double-blind, Parallel-group, Placebo Controlled Study of Esomeprazole i.v. (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour) Administered for 72 Hours to Assess Prevention of Rebleeding in Subjects That Have Undergone Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer - the PUB Study.
Brief Summary: This study is being carried out to see if constant 3 days infusion of Nexium is effective in preventing rebleeding after an endoscopic treatment.


Options:
A: Clinically Significant Rebleeding Within 72 Hours of Continous Infusion of Esomeprazole or Placebo (Within 72 hours)
B: Re-bleeding within 14 days in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy (one year)
C: recurrent bleeding (within 28 days after the first bleeding event)
D: Rebleeding rates and surgical needs

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Supportive Test for Acid-Related Symptoms (STARS II) With Esomeprazole and a Following 7-week, Double-blind, Randomized, Placebo Controlled Treatment Period in Uninvestigated Subjects With Upper Gastrointestinal Symptoms.
Brief Summary: The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment period of 7 weeks.


Options:
A: General impression at last visit in treatment period (4 week); Elimination rate of post-prandial fullness, upper abdominal bloating and early satiety at last visit in treatment period (4 week)
B: After 8 weeks of treatment:; Change of the severity of functional dyspepsia symptoms assessed by the Leeds Dyspepsia Questionnaire); Patient's global assessment of efficacy (proportion of patients symptom-free or markedly improved); Improvement of pain and/or fullness by at least one grade on a 5-grade scale.
C: Response rate of overall symptom improvement after 4-weeks treatment (4 weeks)
D: The primary outcome is whether the patient is a responder or not after 8 weeks treatment.; The primary efficacy outcome is based on symptom score recorded daily during the study in a patient diary.; The patient will judge their symptoms of pain or burning centered in the upper abdomen on a four-graded scale (none, mild, moderate or severe).

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Testing the Re-Engineered Hospital Discharge
Brief Summary: The purpose of this study is to determine if the "Re-Engineered Discharge" will decrease rehospitalization rates and adverse events of patients leaving Boston Medical Center.


Options:
A: Number of patients hospitalized due to COPD worsening (180 days)
B: Total Number of Rehospitalizations (Emergency Department Visits Plus Hospital Admissions) in the 30 Days After Discharge. (30 days after discharge)
C: drug related problems (DRP) (7 days after patient discharge)
D: Time to composite all-cause readmissions/emergency department (ED) visits/death at 3 months (Within 3 months of hospital discharge); Time to composite all-cause readmissions/emergency department (ED) visits/death at 30 days (Within 30 days of hospital discharge)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Testing the Re-Engineered Hospital Discharge
Brief Summary: The purpose of this study is to determine if the "Re-Engineered Discharge" will decrease rehospitalization rates and adverse events of patients leaving Boston Medical Center.


Options:
A: 30-day hospital readmissions (30-days); Emergency Department use (30-days post-discharge)
B: Total Number of Rehospitalizations (Emergency Department Visits Plus Hospital Admissions) in the 30 Days After Discharge. (30 days after discharge)
C: Hospital readmission rate (all cause) (90 days)
D: ADEs (Measured 30 and 90 days after hospital discharge); Medication appropriateness (Measured 30 and 90 days after hospital discharge by the Hanlon et al. Medication Appropriateness Index); Complications related to medications, including the number of hospital readmissions, unscheduled visits to emergency departments or urgent care facilities, and physician visits related to a medication problem or ADE (Measured 30 and 90 days after hospital discharge); Cost-effectiveness of the minimal or enhanced treatment compared to usual care (Measured 30 and 90 days after hospital discharge)

Answer: B